154 related articles for article (PubMed ID: 33140924)
21. Racial Disparities in Delivery Gestational Age among Twin Pregnancies.
Grant JH; Vladutiu CJ; Manuck TA
Am J Perinatol; 2017 Sep; 34(11):1065-1071. PubMed ID: 28591904
[No Abstract] [Full Text] [Related]
22. Progesterone for Prevention of Preterm Birth: Shortcomings and Unintended Consequences of the Orphan Drug Act.
Gee RE; Kuy S; Karas LO
Obstet Gynecol; 2017 Dec; 130(6):1202-1206. PubMed ID: 29112651
[TBL] [Abstract][Full Text] [Related]
23. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
Boelig RC; Schoen CN; Frey H; Gimovsky AC; Springel E; Backley S; Berghella V
Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
[TBL] [Abstract][Full Text] [Related]
24. Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth: a case-control study.
Manuck TA; Watkins WS; Esplin MS; Biggio J; Bukowski R; Parry S; Zhan H; Huang H; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J; Yandell M; Varner MW; Jorde LB;
BJOG; 2018 Feb; 125(3):343-350. PubMed ID: 28139890
[TBL] [Abstract][Full Text] [Related]
25. Quality investigation of hydroxyprogesterone caproate active pharmaceutical ingredient and injection.
Chollet JL; Jozwiakowski MJ
Drug Dev Ind Pharm; 2012 May; 38(5):540-9. PubMed ID: 22329865
[TBL] [Abstract][Full Text] [Related]
26. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
Winer N; Bretelle F; Senat MV; Bohec C; Deruelle P; Perrotin F; Connan L; Vayssière C; Langer B; Capelle M; Azimi S; Porcher R; Rozenberg P;
Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
[TBL] [Abstract][Full Text] [Related]
27. Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.
Feghali M; Venkataramanan R; Caritis S
Semin Perinatol; 2014 Dec; 38(8):516-22. PubMed ID: 25256193
[TBL] [Abstract][Full Text] [Related]
28. The association between 17-hydroxyprogesterone caproate use and postpartum hemorrhage.
Miller ES; Sakowicz A; Roy A; Liu LY; Yee LM
Am J Obstet Gynecol MFM; 2019 May; 1(2):144-147. PubMed ID: 32914089
[TBL] [Abstract][Full Text] [Related]
29. 17 Alpha-hydroxyprogesterone caproate use in a rural state.
Ghahremani T; Phillips A; Magann EF; McCoy H; Whittington J; Ounpraseuth S; Eswaran H
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):6437-6439. PubMed ID: 33899652
[TBL] [Abstract][Full Text] [Related]
30. 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.
Blackwell SC; Gyamfi-Bannerman C; Biggio JR; Chauhan SP; Hughes BL; Louis JM; Manuck TA; Miller HS; Das AF; Saade GR; Nielsen P; Baker J; Yuzko OM; Reznichenko GI; Reznichenko NY; Pekarev O; Tatarova N; Gudeman J; Birch R; Jozwiakowski MJ; Duncan M; Williams L; Krop J
Am J Perinatol; 2020 Jan; 37(2):127-136. PubMed ID: 31652479
[TBL] [Abstract][Full Text] [Related]
31. Unintended consequences--the cost of preventing preterm births after FDA approval of a branded version of 17OHP.
Armstrong J
N Engl J Med; 2011 May; 364(18):1689-91. PubMed ID: 21410391
[No Abstract] [Full Text] [Related]
32. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
[TBL] [Abstract][Full Text] [Related]
33. Spontaneous preterm birth in African-American and Caucasian women receiving 17α-hydroxyprogesterone caproate.
Timofeev J; Singh J; Istwan N; Rhea D; Driggers RW
Am J Perinatol; 2014 Jan; 31(1):55-60. PubMed ID: 23456908
[TBL] [Abstract][Full Text] [Related]
34. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
O'Brien JM; Lewis DF
Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
[TBL] [Abstract][Full Text] [Related]
35. Impact of Obesity on the Rate of Recurrent Spontaneous Preterm Birth in Women Treated with 17-alpha Hydroxyprogesterone Caproate.
Hauspurg A; Lemon LS; Serra AE; Sharma S; Venkataramanan R; Caritis SN
Am J Perinatol; 2018 Jul; 35(9):809-814. PubMed ID: 29294501
[TBL] [Abstract][Full Text] [Related]
36. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ
Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
[TBL] [Abstract][Full Text] [Related]
37. Should we stop prescribing IM progesterone to women with a history of preterm labor?
Dresang L; Vellardita L
J Fam Pract; 2022 Jan; 71(1):E15-E17. PubMed ID: 35587457
[TBL] [Abstract][Full Text] [Related]
38. The end is where we start from: withdrawal of 17-alpha hydroxyprogesterone caproate to prevent recurrent preterm birth.
Nelson DB; Herrera CL; McIntire DD; Cunningham FG
Am J Obstet Gynecol; 2024 Jan; 230(1):1-9. PubMed ID: 37798189
[No Abstract] [Full Text] [Related]
39. Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.
Boelig RC; Locci M; Saccone G; Gragnano E; Berghella V
Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100658. PubMed ID: 35562009
[TBL] [Abstract][Full Text] [Related]
40. Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate.
Co AL; Walker HC; Hade EM; Iams JD
Am J Obstet Gynecol; 2015 Aug; 213(2):233.e1-5. PubMed ID: 25912300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
